The West Bengal government has banned 137 medicines to tackle the proliferation of counterfeit and substandard drugs. This article delves into the reasons behind the ban, the types of medicines affected, and the measures being implemented to ensure drug safety.
In a decisive and far-reaching step to protect public health, the West Bengal government has announced an immediate ban on 137 pharmaceutical products that have been identified as either counterfeit, substandard, or deemed unsafe for consumption. This unprecedented move reflects the growing urgency with which the state is addressing the widespread infiltration of fake and spurious medicines into the healthcare system. The ban follows comprehensive testing and inspections conducted by the state’s health department, in collaboration with national regulatory bodies such as the Central Drugs Standard Control Organisation (CDSCO), which confirmed that many of these medicines failed to meet the prescribed safety and quality benchmarks.
The implications of such a crackdown are enormous—not only in terms of public health, but also in maintaining the credibility of the state’s drug supply chain, which services a population of over 90 million. Counterfeit drugs have long plagued India’s pharmaceutical landscape, with West Bengal emerging as one of the recent hotspots for such illicit activity. From essential antibiotics and fever medications to eye drops and gastrointestinal drugs, the banned list includes a range of commonly used medicines, making the issue even more alarming for patients who rely on these drugs for everyday treatment and chronic illness management.
Health experts have praised the government’s intervention as timely and critical, especially in the aftermath of the COVID-19 pandemic, which created supply chain vulnerabilities that counterfeit drug networks have actively exploited. The pandemic not only heightened demand for certain categories of drugs but also disrupted traditional distribution channels, allowing fake suppliers to enter the market under the guise of legitimate dealers. Reports from the Bengal Chemists & Druggists Association (BCDA) suggest that there has been a staggering 47% rise in counterfeit medicine circulation in West Bengal alone since 2021.
This latest ban represents the first phase of a broader strategy being formulated by the state government to rid the pharmaceutical market of spurious products and hold accountable those responsible for manufacturing, distributing, or selling them. By taking firm legal and administrative action, West Bengal aims to send a strong message to drug cartels and illegal syndicates that public health cannot and will not be compromised for profit.
Furthermore, this move is not just about halting the supply of fake drugs—it also signals an awakening within the healthcare administration to prioritize regulatory compliance, ensure the traceability of medicines through QR codes and serialization, and boost consumer confidence in the formal healthcare infrastructure. It’s a wake-up call not only for pharmacists and distributors, but also for consumers to become more vigilant, verify drug authenticity, and report any suspected cases of counterfeit medicines to authorities.
As the ban begins to be enforced across pharmacies, hospitals, and wholesale markets in West Bengal, it sets a precedent that other Indian states might soon follow. The ripple effect of this decision is likely to be felt across the entire healthcare ecosystem, encouraging better standards, improved regulatory practices, and a renewed commitment to patient safety in India’s pharmaceutical sector.
Understanding the Ban (Expanded)
The decision by the West Bengal government to ban 137 medicines is not arbitrary—it follows a methodical, evidence-based investigation into the quality and origin of several pharmaceutical products circulating in the market. According to senior officials in the state’s Health and Family Welfare Department, these medicines were found to be either counterfeit, unapproved, expired, or manufactured in facilities that lacked proper licensing and quality control infrastructure.
The banned list comprises a wide variety of drug types, including:
-
Antibiotics like amoxicillin and ciprofloxacin
-
Painkillers such as tramadol and diclofenac combinations
-
Antipyretics and anti-inflammatory drugs
-
Gastrointestinal medications like ranitidine and omeprazole variants
-
Ophthalmic solutions (eye drops)
-
Cough syrups and antihistamines
These are not niche or rare medications but ones that feature prominently in prescriptions for routine illnesses. The sheer diversity of the drugs included in the ban reveals the deep penetration of counterfeit substances into West Bengal’s public and private healthcare systems.
The ban was formalized after quality checks were conducted at the state drug testing laboratory, supported by data from the Central Drugs Standard Control Organisation (CDSCO), which issues monthly alerts on Not of Standard Quality (NSQ) drugs. Out of the 137 medicines flagged, many had failed basic pharmacopoeial tests such as sterility, assay value, pH, and impurity profiles—standards mandated under the Drugs and Cosmetics Act, 1940.
This move is also a direct response to rising public and medical concern. Doctors across government hospitals and private clinics had been reporting repeated instances of “drug failure”—patients showing no improvement even after taking prescribed medicines. In some cases, the use of fake or substandard drugs led to severe adverse drug reactions (ADRs), extended hospital stays, and avoidable deaths.
By implementing the ban, the West Bengal government aims not only to protect patient lives but also to restore confidence in the pharmaceutical sector, which is among India’s most important economic and public service segments.
The Counterfeit Drug Crisis in West Bengal
The phenomenon of counterfeit drugs is neither new nor limited to West Bengal. However, the situation in the state has become increasingly dire in recent years, prompting urgent intervention.
Following the pandemic, drug regulatory bodies in India saw a spike in fake drug seizures. In West Bengal, the trend became alarmingly visible in 2023–2025, especially in Kolkata, North 24 Parganas, and Murshidabad. A report released by the Bengal Chemists and Druggists Association (BCDA) revealed that fake medicines accounted for nearly half of all drugs tested in surprise raids.
These counterfeit drugs often mimic the packaging of reputable brands, making it almost impossible for untrained eyes—be they pharmacists or consumers—to identify them. However, the chemical composition either lacks the active pharmaceutical ingredient (API) or contains toxic or incorrect substances, which can be deadly or ineffective.
One major incident that catalyzed state action occurred in Titagarh, where the Directorate of Drug Control unearthed a massive warehouse filled with spurious drugs worth over ₹34 lakh. The products were allegedly smuggled in bulk from Uttar Pradesh and Jharkhand, labeled under fake brand names, and distributed across various retail points in the state.
According to sources in the police department, these drug rings often operate in highly organized networks. They function across state borders and have ties with some unscrupulous suppliers, distributors, and even elements within the pharmacy trade. This raises the stakes for state governments like West Bengal, which must now not only regulate local manufacturers but also coordinate inter-state operations and surveillance mechanisms to identify supply chain vulnerabilities.
The West Bengal government’s decision to ban 137 medicines is being hailed as a long-overdue crackdown, but health experts caution that this is only the beginning of what must be a prolonged war against a deeply embedded menace.
Impact on Public Health and the Healthcare System
The proliferation of counterfeit medicines has a catastrophic impact on public health. When a patient consumes medicine, there is an inherent trust that the product is safe, scientifically tested, and effective. Counterfeit and substandard medicines break that trust—and the consequences can be fatal.
Among the gravest dangers are:
-
Therapeutic Failure: Patients with infections, chronic diseases, or post-operative needs who consume ineffective medications may suffer deterioration in health, prolonged illness, and relapses.
-
Drug Resistance: Incomplete or fake antibiotic treatments are known to cause antimicrobial resistance (AMR), which has become one of the top global health threats.
-
Toxic Reactions: Some counterfeit drugs contain wrong or contaminated ingredients, leading to poisoning, organ damage, and even death.
-
Maternal and Child Health Risks: Pregnant women and children, who require precise dosages and safe formulations, are especially vulnerable.
-
Economic Burden: Families spend thousands on repeated hospital visits, tests, and second-round medications due to failure of the first course, often pushing low-income households further into poverty.
The healthcare system itself is burdened when patients return to hospitals with unresolved symptoms or deteriorating conditions. This leads to increased bed occupancy, pressure on doctors, misuse of diagnostic resources, and a general erosion of faith in both government and private medical services.
Through the ban, the West Bengal government aims to halt this destructive cycle and lay the groundwork for a safer pharmaceutical landscape—one where quality, traceability, and safety are non-negotiable.
Government’s Response and Measures
Following the announcement that the West Bengal government bans 137 medicines, Chief Minister Mamata Banerjee’s administration has moved swiftly to implement supplementary measures to prevent recurrence. The Health & Family Welfare Department issued immediate instructions to all Chief Medical Officers of Health (CMOHs), Drug Inspectors, and hospital superintendents to remove the banned drugs from their inventories and ensure compliance within a 72-hour timeframe.
At the press briefing in Nabanna, the state’s Chief Secretary outlined a five-point action plan aimed at tackling the counterfeit drug menace:
-
Statewide Inventory Audit: All hospitals and pharmacies—public and private—will undergo rigorous inventory checks, with random sampling of stocked medicines.
-
Pharmacy Compliance Check: Chemists must now maintain digital records of suppliers and submit quarterly reports on medicine purchases to the State Drug Control Directorate.
-
Task Force Creation: A joint enforcement task force comprising health officials, local police, and excise officers will monitor medicine movement across border districts.
-
Public Helpline & Reporting Mechanism: A 24/7 helpline is being set up where citizens can report suspicious drugs or illegal sales.
-
Training for Pharmacists: The state will organize capacity-building workshops to help pharmacists identify fake packaging, expired drugs, and verify QR codes linked to batch-level information.
The government is also coordinating with the National Pharmaceutical Pricing Authority (NPPA) and CDSCO to ensure that similar drugs from other states don’t leak into West Bengal’s supply chain.
In an unprecedented step, the West Bengal Drug Control Directorate has partnered with IIT-Kharagpur to develop a blockchain-based tracking system to enhance traceability of medicine batches. The goal is to make every drug packet traceable back to its origin through a QR-code verification system accessible via mobile apps.
West Bengal Government Bans 137 Medicines: Challenges Ahead
While the government’s efforts are commendable, experts warn that enforcement will face substantial obstacles. The pharmaceutical distribution network in India, particularly in populous states like West Bengal, is highly fragmented. With thousands of wholesalers and retailers spread across rural and urban zones, maintaining uniform vigilance is a daunting task.
Some key challenges include:
-
Lack of Trained Personnel: The number of qualified drug inspectors is far below what is required for real-time, statewide surveillance.
-
Deep-Rooted Corruption: In some instances, low-level corruption and bribery within inspection systems allow non-compliant traders to operate freely.
-
Low Public Awareness: Many patients in rural areas are unaware of the risks of fake drugs and do not verify the source or expiry dates.
-
Online Pharmacy Loopholes: E-pharmacy platforms, while convenient, often escape strict scrutiny, enabling counterfeit sellers to infiltrate with fake listings.
The West Bengal government has acknowledged these systemic hurdles and plans to submit a proposal to the Union Ministry of Health requesting financial and logistical support to bolster inspection and training mechanisms.
Legal and Pharmaceutical Industry Reaction
The legal framework supporting drug regulation in India stems from the Drugs and Cosmetics Act, 1940, and the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Violation of quality standards under these laws can lead to fines, license cancellation, and imprisonment.
In response to the news that the West Bengal government bans 137 medicines, several FIRs have already been lodged against pharmaceutical companies and distributors. A few major wholesale dealers in Burra Bazar and Barasat have had their licenses suspended, pending further investigation. Police raids are also underway in Cooch Behar, Howrah, and Nadia.
The pharmaceutical industry, however, has issued mixed responses. While responsible manufacturers welcomed the crackdown, citing it as a necessary step to cleanse the market, some smaller traders expressed concern over lack of prior warning and potential disruption to business. The Bengal Chemists and Druggists Association (BCDA) has asked for a list of approved substitutes to help pharmacies serve patients without delay.
Meanwhile, legal experts argue that the state must follow due process to avoid arbitrary seizures. Advocate Arindam Das, a Kolkata-based pharma law expert, stated,
“The state is absolutely justified in banning harmful drugs. However, transparency in testing and ensuring manufacturers can appeal findings is essential to prevent misuse of the ban mechanism.”
National Implications and Ripple Effect
The announcement that the West Bengal government bans 137 medicines could have a far-reaching impact beyond the borders of the state. Public health experts say that other Indian states may follow suit, especially those grappling with similar counterfeit drug problems, such as Uttar Pradesh, Bihar, and Madhya Pradesh.
The Union Health Ministry has taken note of the action and has reportedly asked the Central Drugs Laboratory in Kolkata to cross-check the banned list and issue advisories to other states. If these medicines are found circulating across states, a national-level ban or recall may follow.
Additionally, this move could accelerate the central government’s push toward a nationwide digital drug-tracking system. Under the “Track and Trace” initiative, each strip or vial of medicine will carry a unique code allowing regulators and consumers to verify its authenticity from manufacturing to retail.
Internationally, the step has been welcomed by global health bodies. Representatives from the World Health Organization (WHO) and Médecins Sans Frontières (MSF) have lauded the state’s commitment to tackling fake drugs, which are a menace not only in India but across developing nations.
The West Bengal government’s ban on 137 medicines marks a watershed moment in India’s fight against counterfeit and substandard drugs. It sends a strong message that public health takes precedence over profiteering, and the safety of every patient must be non-negotiable.
However, this decisive move must be accompanied by consistent enforcement, robust monitoring, and proactive public engagement. If implemented efficiently, this crackdown could serve as a template for other states and even the Union government to adopt stronger drug regulation frameworks.
At its core, this action isn’t just about banning a few medicines—it’s about rebuilding public trust in the healthcare system, holding manufacturers accountable, and preventing future tragedies caused by fake drugs.
As West Bengal tightens its grip on pharmaceutical safety, the rest of India—and indeed the world—will be watching closely.
Do Follow
CDSCO Alerts on NSQ Drugs
Also read: Home | Channel 6 Network – Latest News, Breaking Updates: Politics, Business, Tech & More
